Ask AI
Managing AEs in Relapsed ES-SCLC

CE / CME

Mitigating and Managing AEs Associated With Newer Agents for Relapsed ES-SCLC

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: December 02, 2025

Expiration: June 01, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Tarlatamab [prescribing information]. Thousand Oaks, CA: Amgen, Inc.; 2024
  2. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063-2075.
  3. Sands J, Cho BC, Ahn MJ, et al. Tarlatamab sustained clinical benefit and safety in previously treated SCLC: DeLLphi-301 phase 2 extended follow-up. Presented at: World Conference on Lung Cancer; September 7-10, 2024. Abstract OA10.03.
  4. Mountzios G, Sun L, Cho BC, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393:349-361.
  5. Khadka RH, Sakemura R, Kenderian SS, et al. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 2019;11:851-857.
  6. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.
  7. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-638.
  8. Sands JM, Stéphane Champiat, Hummel H, et al. Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer. Cancer. 2025;131:e35738.
  9. Géraud A, Hueso T, Laparra A, et al. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur J Cancer. 2024;205:114075.
  10. Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology. 2021;32:34-48.
  11. Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal for ImmunoTherapy of Cancer. 2020;8:e001511.
  12. Carlisle JW, O’Reilly K, Canaslan K, et al. Implementation of tarlatamab treatment for small cell lung cancer using an outpatient care program. Presented at: American Society of Clinical Oncology Congress; May 30-June 3, 2025. Abstract 8106.
  13. Patel S, Petty WJ, Sands JM. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer. Ther Adv Med Oncol. 2021;13:17588359211020529.
  14. Lurbinectedin. [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; 2025.
  15. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncology. 2020;21:645-654.
  16. Paz-Ares L, Borghaei H, Liu SV, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025;405:2129-2143.
  17. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: small-cell lung cancer. v.2.2026. Accessed November 11, 2025.
  18. Atezolizumab [prescribing information]. South San Francisco, CA: Genetech; 2025.
  19. Durvalumab. [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; 2025.
  20. Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619-630.
  21. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7:100408.
  22. Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncology. 2021;22:51-65.
  23. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2015;27:559-574.
  24. Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019;16:535-548.
  25. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-1768.
  26. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Management of immunotherapy-related toxicities v.1.2025. Accessed November 11, 2025.